N/A
Completed N=2,554
Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
Papillomavirus Vaccines
Source: ClinicalTrials.gov NCT03501992 ↗
Enrolled (actual)
2,554
Serious AEs
—
Results posted
Oct 2024
Primary outcomePrimary: Human Papillomavirus or HPV-vaccine-dose Receipt — 782; 578; 408; 1056 Participants
Summary
Each year the human papillomavirus (HPV) causes 30,000 cancers in the United States despite the availability of very effective and safe vaccines. Uptake of the HPV vaccine has been disappointingly low and lags behind other adolescent vaccines. This study seeks to test interventions targeting health care system, provider, and patient factors to improve the population uptake of the HPV vaccine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Human Papillomavirus or HPV-vaccine-dose Receipt |
782; 578; 408; 1056 | — |
| SECONDARY Initiation |
482; 329; 251; 490 | — |
| SECONDARY Completion |
300; 249; 157; 566 | — |
Eligibility Criteria
Inclusion Criteria
- Empaneled in one of the six participating primary care practices
- 11 to 12 years of age at the first day of each of the 12-month-long steps
- Due during that 12-month-long step for at least one dose of the HPV vaccine
Exclusion Criteria
- Not empaneled in one of the six participating practices
- Empaneled in one of the six participating practices but less than 11 years of age or more than 12 years of age on the first day of each 12 month long step
- Not due during that 12-month-long step for a dose of HPV vaccine.
Data sourced from ClinicalTrials.gov (NCT03501992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.